Angioedema related to angiotensin inhibitors

Journal of Pharmacy Practice

Volumn 27, Issue 5, 2014, Pages 461-465

  Knecht, Stephanie E ^a   Dunn, Steven P ^b   Macaulay, Tracy E ^c  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

angioedema; angiotensin converting enzyme inhibitors (ACEI); angiotensin receptor blockers (ARBs); bradykinin; renin angiotensin aldosterone system (RAAS) blockade

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; TELMISARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CROSS REACTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; HUMANS; HYPERTENSION; INCIDENCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84908887244     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546101     Document Type: Article

References (30)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007 ; 13 ((8 suppl B)). 9-20
2. Campo P, Fernandez TD, Canto G, et al. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013 ; 13 ((4)). 337-344
3. Beavers CJ, Dunn SP, Macaulay TE. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother. 2011 ; 45 ((4)). 520-524
4. Gabb GM, Ryan P, Wing LM, et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med. 1996 ; 26 ((6)). 777-782
5. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy. 2010 ; 40 ((1)). 50-61
6. Lerch M. Drug-induced angioedema. Chem Immunol Allergy. 2012 ; 97: 98-105
7. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002 ; 347 ((8)). 621-622
8. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010 ; 47 ((13)). 2161-2169
9. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006 ; 26 ((4)). 725-737
10. Hiyoshi H, Yayama K, Takano M, et al. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension. 2004 ; 43 ((6)). 1258-1263
11. Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy. 2007 ; 62 ((8)). 842-856
12. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012 ; 110 ((3)). 383-391
13. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000 ; 139 ((4)). 609-617
14. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 ; 362 ((9386)). 772-776
15. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 ; 372 ((9644)). 1174-1183
16. Haymore BR, Yoon J, Mikita CP, et al. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008 ; 101 ((5)). 495-499
17. Haymore BR, DeZee KJ. Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol. 2009 ; 103 ((1)). 83-84
18. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012 ; 12 ((4)). 263-277
19. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 ; 374 ((9704)). 1840-1848
20. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 ; 327 ((10)). 669-677
21. The SOLVD Investigattors. N Engl J Med. 1992 ; 327 ((10)). 685-691
22. The SOLVD Investigators. N Engl J Med. 1991 ; 325 ((5)). 293-302
23. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000 ; 342 ((3)). 145-153
24. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004 ; 351 ((20)). 2058-2068
25. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ; 345 ((23)). 1667-1675
26. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 ; 362 ((9386)). 777-781
27. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 ; 362 ((9386)). 767-771
28. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet. 2003 ; 362 ((9386)). 759-766
29. The CONSENSUS trial study group. N Engl J Med. 1987 ; 316 ((23)). 1429-1435
30. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des. 2007 ; 13 (13). 1335-1345